The FDA wants more data on Theravance's infection treatment telavancin but won't require the developer to launch a new trial. Regulators want more input on evaluating risk, says Theravance, including more data on risks related to specific kidney-related conditions. An FDA panel has recommended the drug, which guards against hospital-acquired pneumonia and other infections. Theravance release